Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Renal Cell 18Neoplasms 12Kidney Neoplasms 6Breast Neoplasms 6Stomach Neoplasms 4Neoplasm Metastasis 4Gastrointestinal Stromal Tumors 4Carcinoma, Non-Small-Cell Lung 4Solid Tumors 3Prostatic Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Pancreatic Neoplasms 3Leukemia, Myeloid, Acute 3Glioblastoma 3Unspecified Adult Solid Tumor, Protocol Specific 2Primary Myelofibrosis 2Myeloproliferative Disorders 2Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Chronic-Phase 2Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 2Leukemia, Myeloid, Accelerated Phase 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hodgkin Disease 2Glioma 2Colorectal Neoplasms 2Clear-cell metastatic renal cell carcinoma 2Brain Neoplasms 2Advanced Cancer 2

Interventions

Vorinostat 2nintedanib 1dactolisib 1avelumab 1Vinorelbine 1Sunitinib 1Hydroxychloroquine 1Dasatinib 1DOXO-EMCH 1Cetuximab 1BN 80927 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Malignant Solid Tumour × Sunitinib × Clear all
NCT01286896 2025-07-10

Use of Individual Pharmacokinetically (PK)-Guided Sunitinib Dosing: A Feasibility Study in Patients With Advanced Solid Tumors

The Netherlands Cancer Institute

Phase 1 Completed
43 enrolled
Other solid neoplasm

Malignant Solid Tumour

Data powered by HemOnc (CC BY 4.0) Colophon âš¡